Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.

Trial Profile

Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Irinotecan (Primary) ; Temozolomide
  • Indications Glioma; Medulloblastoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Feb 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top